Bioventus in 2021: 5 updates to know

Biologics

Since launching its initial public offering in February, orthobiologics company Bioventus marked several notable achievements, including a multimillion-dollar acquisition.

Five updates:

1. Bioventus launched its initial public offering: 7.35 million shares of its Class A common stock priced between $16 and $18 per share.

2. Larry Chen was appointed as managing director of the company's China and Asian Pacific region. 

3. Bioventus has acquired rehabilitation solutions company Bioness for $45 million upfront consideration, with up to $65 million contingent consideration. 

4. In the first quarter of 2021, Bioventus saw year-over-year net income growth, roping in $24.5 million

5. Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable. The allograft is optimal for minimally invasive surgeries and can be used in a various spine and foot and ankle procedures.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like